vorasidenib
servier
['indigo']
the first phase 3 clinical trial of a molecularly targeted therapy for low grade idh-mutant #glioma showed positive results and opens the door to new possibilities for patients. the indigo trial was presented during the #asco23 plenary.
press release 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090